Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 6/20 | 0.70 |
| ▸ | GABBR1 | Q9UBS5 | 6/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351702 | 1.00 | GABBR2 (0.70) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL660764 | 0.88 | FNTA (0.54) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| Hydrochloric Acid SCHEMBL7334847 | 0.86 | FNTA (0.52) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL28316668 | 0.83 | FFAR1 (0.47) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL28801346 | 0.83 | GABBR2 (0.72) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| Phenibut SCHEMBL9545047 | 0.82 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| Phenibut SCHEMBL340838 | 0.82 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| Phenibut SCHEMBL351501 | 0.82 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL13940816 | 0.81 | GABBR2 (0.70) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| Baclofen SCHEMBL5556250 | 0.81 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536194-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | EsoCap AG (CH) | 2025-04-16 | — | — | EP | claimed |
| EP-3723745-B1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2024-06-19 | — | — | EP | claimed |
| WO-2023237426-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2023-12-14 | — | — | WO | claimed |
| WO-2023178183-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND ALPHA-2 ADRENERGIC RECEPTORS FOR TREATMENT OF STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-09-21 | — | — | WO | claimed |
| US-9353057-B2 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT, INC. (US) | 2016-05-31 | — | — | US | claimed |
| WO-2011113904-A1 | MEDICAMENTS FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-09-22 | — | — | WO | claimed |
| EP-0023192-B1 | CYCLOPEPTIDES AND PHARMACEUTICAL PREPARATIONS THEREOF, PROCESS FOR THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1984-03-28 | — | — | EP | claimed |
| US-4328214-A | OCTAPEPTIDES, ANTIDIABETICS, TREATING BLOOD LOSSES IN GASTROINTESTINAL TRACT | CIBA-GEIGY CORPORATION (US) | 1982-05-04 | — | — | US | claimed |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-06-12 | — | — | US | disclosed |
| CN-119899141-A | Chiral pentafluorophenyl urea compound and preparation method and application thereof | 沈阳化工大学 | 2025-04-29 | — | — | CN | disclosed |
| EP-4536194-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | EsoCap AG (CH) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023237426-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023178183-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND ALPHA-2 ADRENERGIC RECEPTORS FOR TREATMENT OF STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-3599246-A1 | MEANS AND METHODS FOR SYNTHESIZING PRECURSORS OF Y-AMINOBUTYRIC ACID (GABA) ANALOGS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2020-01-29 | — | — | EP | disclosed |
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2006050471-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF SULFINIC ACIDS, METHODS OF SYNTHESIS, AND USE | XENOPORT, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006050472-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF 3-AMINOPROPYLPHOSPHONOUS AND -PHOSPHINIC ACIDS | XENOPORT, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20050107334-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005019163-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-4328214-A | OCTAPEPTIDES, ANTIDIABETICS, TREATING BLOOD LOSSES IN GASTROINTESTINAL TRACT | CIBA-GEIGY CORPORATION (US) | 1982-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | APEH, AASDHPPT, AGPS | GABBR2 388/4885GABBR1 497/4885LMNA 3723/4885 |
| US-20050107334-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, ABAT, SI | GABBR2 6/4885GABBR1 7/4885LMNA 3875/4885 |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | GABRB2, GABRB1, ADRB2 | GABBR2 13/4885GABBR1 19/4885LMNA 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.